Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kim Shah

- PMLiVE

NHS to move ahead with Pfizer/BioNTech bivalent COVID-19 vaccine roll-out

The autumn booster programme launches today

- PMLiVE

Qureight announces world’s first digital biomarker for lung fibrosis will ‘transform’ clinical trials

The AI-based Lung8 imaging software picked up differences in response between patients who had an experimental drug compared with those who took a placebo

- PMLiVE

Novavax’s COVID-19 vaccine candidate receives CHMP recommendation for use as a booster

The protein-based vaccine induced a ‘robust antibody response’ when used as a heterologous third booster dose, data from a UK-sponsored trial showed

- PMLiVE

Pfizer/BioNTech BA.1 COVID-19 booster receives CHMP recommendation

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Moderna’s Omicron BA.1 targeting bivalent booster recommended by CHMP for use in EU

Results from a phase 2/3 trial demonstrated mRNA-1273.214 had superior neutralising antibody response against Omicron compared to the currently authorised booster

Advancing Precision Medicine in Oncology

Jerome Madison, Host of The Precision Medicine Podcast, shares his leadership lessons and tips for building and training new sales teams in the era of precision medicine. He also dives...

Impetus Digital

- PMLiVE

Moderna granted FDA authorisation for emergency use of BA.4/BA.5-targeting bivalent COVID-19 booster

The application was based on preclinical data and clinical trial data available from a phase 2/3 study evaluation of the company's BA.1 Omicron-targeting bivalent booster candidate

- PMLiVE

Pfizer and BioNTech granted FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The companies outlined that the original and bivalent vaccines will be supplied under their existing supply agreement with the US government

- PMLiVE

Novavax’s COVID-19 vaccine candidate approved by MHRA for adolescents aged 12 to 17

Data from an ongoing phase 3 paediatric trial demonstrated Nuvaxovid produced 80% clinical efficacy in this age group

- PMLiVE

Moderna sues Pfizer/BioNTech over COVID-19 vaccine technology

The company believes two key features of its patented mRNA technology platform were copied

- PMLiVE

Study found Pfizer’s Paxlovid only helped over 65s avoid hospitalisation and death

Researchers studied data from 109,000 patients – nearly all of whom had been vaccinated against COVID-19, been previously infected, or both

- PMLiVE

MIT researchers develop AI model to detect Parkinson’s from breathing patterns

The tool uses a series of connected algorithms that can assess if someone has PD from their nocturnal breathing

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links